GSC
CASI

Ground Swell Capital’s CASI Pharmaceuticals CASI Stock Holding History

Ground Swell Capital’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,135
Closed -$16.8K – 100
2025
Q3 		$16.8K Buy
+10,135
New +$18.1K 0.04% 115
2022
Q1 		– Sell
-1,864
Closed -$15K – 76
2021
Q4 		$15K Buy
+1,864
New +$18.6K 0.09% 62

Other funds holding CASI

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Ground Swell Capital's CASI Position: Q4 2025 in Review

Ground Swell Capital sold out of CASI Pharmaceuticals (CASI) in Q4 2025, closing a stake of 10,135 shares — an estimated $16.8K sold.

Ground Swell Capital first reported a position in CASI in Q4 2021 and held it in 2 quarters. The position peaked at $16.8K in Q3 2025. 16 funds tracked by Wall St. Rank hold CASI as of Q4 2025.

  • Ground Swell Capital reported no remaining CASI Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ground Swell Capital sold 10,135 CASI Pharmaceuticals shares in Q4 2025, an estimated $16.8K.
  • Ground Swell Capital first reported a position in CASI Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Ground Swell Capital's CASI Pharmaceuticals position peaked at $16.8K in Q3 2025.
  • 16 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2025.

Based on Ground Swell Capital's 13F filing for Q4 2025, filed 4 Feb 2026.